In a small pivotal study, all seven patients with AHA, initially treated with high-dose activated prothrombin complex concentrate followed by post-hemostasis reduced-dose activated prothrombin complex concentrate as maintenance therapy until FVIII inhibitor titer was less than 50%, experienced no recurrence of bleeding. Here, F8 is linked to autoimmune hemolytic anemia.